Mohit Rawat, Chief Executive Officer at the Myricx Bio, shared a post on LinkedIn:
“I am very excited to announce that I will be joining Myricx Bio as CEO.
Myricx Bio has the potential to become a leader in ADC therapeutics for cancer treatment, with a first-in-class and highly differentiated ADC payload platform that leverages NMT inhibition. The NMTi platform has the potential to address the key unmet needs of ADC therapeutics to overcome payload resistance, improve tolerability, and also deliver efficacy in difficult to treat cancer types.
Myricx Bio is backed by world-class and highly experienced investors (Sofinnova Partners, Novo Holdings, Abingworth, Brandon Capital, Eli Lilly and Company, British Business Bank and Cancer Research Horizons) and have attracted a talented team to help accomplish its mission. I look forward to working with the team and the board
Full press release here.”
More posts featuring Myricx Bio on OncoDaily.